RainDance Launches ThunderBolts Next-Gen Sequencing Cancer Panel
This article was originally published in The Gray Sheet
Executive Summary
RainDance Technologies announced the official launch of the ThunderBolts cancer panel this week at the American Association for Cancer Research annual meeting in San Diego, where researchers demonstrated the system’s ability to genetically profile various types of tumors for as little as $100 per sample.
You may also be interested in...
FDA Approves First Next-Generation DNA Sequencing Platforms
Illumina’s MiSeqDx instrument and MiSeqDx Universal Kit, granted de novo approval, allow clinicians to “develop and validate sequencing of any part of a patient’s genome,” FDA says.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.